Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk

Shares of Eli Lilly (LLY) rose more than 3% on Tuesday after reporting long-term data from the late-stage SURMOUNT-1 study. Data from this study showed that treatment with tirzepatide over three years lowered the risk of developing type 2 diabetes (T2D) by 94% compared with placebo, in obese or overweight adults with pre-diabetes.A dual GIP and GLP-1 receptor agonist, tirzepatide is the active ingredient used in the company’s two blockbuster medications — obesity drug Zepbound and diabetes drug Mounjaro.The ...